Chemir Launches IQsynthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Chemir Launches IQsynthesis


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Chemir Launches IQsynthesis

Patricia Van Arnum

St. Louis, MO (Sept. 15)—Chemir Analytical Services (Maryland Heights, MO, www.chemir.com) has launched IQsynthesis (www.IQsynthesis.com), formerly known as Gateway Chemical Technology, Inc. Chemir acquired Gateway Chemical Technology, which provides custom synthesis and process development services, in May 2006.

“Clients have been requesting synthetic chemistry services, and we sought an acquisition to best fill this need,” explains Shri Thanedar, CEO of Chemir Analytical Services. 

IQsynthesis offers synthesis services for pharmaceutical intermediates; bioorganic compounds; and specialty, fine, and agrochemicals. Other services include synthesis of analytical standards, metabolites, tox lot batches, stable isotope-labeled compounds, intermediates, custom surfactants, combinational platforms, extraction and purification of natural products, and process development. Plans are underway to expand laboratory space and staff as well as develop infrastructure and systems for CGMP-regulated synthesis.

The Chemir group of companies include IQsynthesis; Chemir Analytical Services; Azopharma, a pharmaceutical contract service provider; and CAS-MI, a laboratory serving the paints, coatings, and polymer industries. Total sales for the company are expected to reach $24 million in 2006, with an anticipated goal of reaching $50 million by 2009.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here